Sophia Lee
Harvard University
Network
Latest external collaboration on country level. Dive into details by clicking on the dots.
Publication
Featured researches published by Sophia Lee.
AIDS Research and Human Retroviruses | 2000
Andrew Wiznia; Kenneth Stanley; Paul Krogstad; George M. Johnson; Sophia Lee; J. McNamara; Jack Moye; J.B. Jackson; H. Mendez; R. Aguayo; Arry Dieudonne; Andrea Kovacs; Mahrukh Bamji; E. Abrams; S. Rana; J. Sever; Sharon Nachman
One hundred eighty-one antiretroviral-experienced, protease inhibitor-naive, clinically stable HIV-infected children between 4 months and 17 years of age were randomly assigned to receive one of four combination regimens to evaluate the change in plasma HIV RNA, safety, and tolerance when changing antiretroviral therapy to a protease inhibitor-containing combination regimen. All four regimens contained stavudine; in addition children received nevirapine plus ritonavir, lamivudine plus nelfinavir, nevirapine plus nelfinavir, or lamivudine plus nevirapine plus nelfinavir. Twelve additional children chose to receive stavudine plus lamivudine plus nelfinavir, with nelfinavir given bid, rather than tid as for the main regimens. Overall, 51% (89/176; 95% CI 43-58%) of the children on the randomized portion of the study had an HIV RNA response (< or =400 copies/ml) on at least two of the three HIV RNA determinations taken at Weeks 8, 12, and 16. At Week 24 the proportion of children with an HIV RNA response still on initial therapy was 47% (83/176; 95% CI 40-55%) and ranged from 41 to 61% for the four randomized treatment arms. Rash was frequently seen (27%) on the treatment arms containing nevirapine. At Week 24 64% (7/11, 95% CI 31-89%) of the children on the bid nelfinavir combination regimen were still on initial therapy with an HIV RNA response as compared with 46% (23/50; 95% CI 32-61%) on the corresponding tid nelfinavir combination regimen. A change in antiretroviral therapy to a protease inhibitor-containing regimen was associated with a virological response rate of approximately 50% for this patient population.
The Journal of Infectious Diseases | 2000
William Borkowsky; Kenneth Stanley; Steven D. Douglas; Sophia Lee; Andrew Wiznia; Stephen I. Pelton; Ram Yogev; Kenneth McIntosh; Sharon Nachman
The response of 40 immunologic parameters was studied for 147 clinically stable, protease inhibitor-naive, human immunodeficiency virus (HIV)-infected children aged 2-17 years when antiretroviral therapy was changed to either a dual nucleoside analogue regimen or a protease inhibitor-containing regimen. Immunologic response to therapy, as measured by lymphocyte subsets, 3-color flow cytometric measures, and lymphoproliferative assays, were investigated for changes in weeks 44 and 48. The most significant changes after baseline that were associated with the administration of a protease inhibitor-containing regimen were seen for percentages of CD8(+)/CD38(+)/HLA-DR(+), CD8(+)/CD95(+)/CD28(-), and CD8. The percentages of CD8(+)/CD38(+)/HLA-DR(+) and CD8(+)/CD95(+)/CD28(-) decreased from baseline medians of 33% and 46% to medians of 18% and 30% at week 44 (P<.0001 for both). Median CD4 cell count increased 168 cells/microL (from 694 cells/microL to 862 cells/microL; P=.02) by week 48 in this clinically stable population. Changes in lymphoproliferative responses to HIV antigens and recall antigens did not increase over time and between groups.
European Journal of Pharmacology | 1993
David Y. Cheng; Timothy J. McMahon; Bracken J. DeWitt; Gregory C. Carroll; Sophia Lee; William A. Murphy; Kamal G. Bitar; David H. Coy; Philip J. Kadowitz
Responses to pituitary adenylate cyclase activating polypeptide (PACAP)-38 were investigated and compared with responses to PACAP-27 and vasoactive intestinal polypeptide (VIP) in the pulmonary vascular bed of the intact-chest cat under constant flow conditions. Under low resting tone baseline conditions, injections of PACAP-38 had little or no effect on lobar arterial pressure; however, when tone in the pulmonary vascular bed was raised to a high steady level (35-40 mm Hg) with U46619, intralobar injections of PACAP-38 caused dose-related decreases in lobar arterial pressure without altering left atrial pressure. The peptide induced biphasic changes in systemic arterial pressure. PACAP-38 was more potent than VIP in decreasing lobar arterial pressure, and both peptides were significantly less potent than PACAP-27 in dilating the pulmonary vascular bed. The present data show that PACAP-38 has significant vasodilator activity in the pulmonary vascular bed of the cat, and that the 27 amino acid form of the peptide is approximately 3-fold more potent than PACAP-38.
Pediatric Infectious Disease Journal | 2002
Ram Yogev; Sophia Lee; Andrew Wiznia; Sharon Nachman; Kenneth Stanley; Stephen I. Pelton; Lynne M. Mofenson; Susan A. Fiscus; Eleanor Jimenez; Mobeen H. Rathore; Mary E. Smith; Lin Ye Song; Kenneth McIntosh
BACKGROUND The efficacy and tolerance of switching from zidovudine (ZDV) and lamivudine (3TC) in clinically stable HIV-infected children with incomplete viral suppression to stavudine (d4T), nevirapine (NVP) and ritonavir (RTV) has not been determined. Aim. To evaluate the safety, tolerance, antiviral activity and immunologic changes after the change to a three drug combination. METHODS During a clinical trial in which HIV-infected antiretroviral-experienced children were initially randomized to receive d4T/RTV, ZDV/3TC/RTV or ZDV/3TC (Step 1), 48 children who had HIV RNA > or = 10,000 copies/ml after > or = 12 weeks of ZDV/3TC therapy in Step 1 were switched to d4T/NVP/RTV in Step 2. The proportion of children receiving therapy with HIV RNA < or = 400 copies/ml at Study Weeks 24 and 48 receiving d4T/NVP/RTV in Step 2 were compared with children receiving RTV-containing regimens in Step 1. RESULTS At 24 weeks of treatment with d4T/NVP/RTV in Step 2, 48% (23 of 48) of children had HIV RNA < or = 400 copies/ml compared with 34% (31 of 92) and 47% (44 of 93) receiving d4T/RTV or ZDV/3TC/RTV for 24 weeks in Step 1; at 48 weeks virologic response was 44, 27 and 42% in Step 2 d4T/NVP/RTV, Step 1 d4T/RTV and Step 1 ZDV/3TC/RTV arms, respectively. CONCLUSIONS A delay of 7 to 12 months in the initiation of protease inhibitor-containing combination therapy in children receiving dual nucleoside analogue therapy did not adversely affect the RNA response during the first 48 weeks of treatment.
Pediatric Research | 1999
George M. Johnson; Kenneth Stanley; Andrew Wiznia; Paul Krogstad; Sophia Lee; Francesca T. Aweeka; Sandra Hayashi; Sharon Nachman
Preliminary Evaluation of Nelfinavir (NFV) Pharmacodynamics in Stable Antiretroviral Experienced HIV-Infected Children Following Initiation of HAART (PACTG 377)
JAMA | 1999
Mary Culnane; MaryGlenn Fowler; Sophia Lee; George McSherry; Michael T. Brady; Karen O'Donnell; Lynne M. Mofenson; Steven L. Gortmaker; David Shapiro; Gwendolyn B. Scott; Eleanor Jimenez; Ellen C. Moore; Clemente Diaz; Patricia M. Flynn; Bethann E. Cunningham; James M. Oleske
Pediatrics | 2002
Russell B. Van Dyke; Sophia Lee; George M. Johnson; Andrew Wiznia; Kathleen Mohan; Kenneth Stanley; Edward Morse; Paul A. Krogstad; Sharon Nachman
Pediatrics | 2006
Molly Nozyce; Sophia Lee; Andrew Wiznia; Sharon Nachman; Lynne M. Mofenson; Mary E. Smith; Ram Yogev; Kenneth McIntosh; Kenneth Stanley; Stephen I. Pelton
JAMA | 2000
Sharon Nachman; Kenneth Stanley; Ram Yogev; Stephen Pelton; Andrew Wiznia; Sophia Lee; Lynne M. Mofenson; Susan A. Fiscus; Mobeen H. Rathore; Eleanor Jimenez; William Borkowsky; Jane Pitt; Mary E. Smith; Barbara Wells; Kenneth McIntosh
JAMA | 1994
Kathleen D. Mendelsohn; Linda Z. Nieman; Krista Isaacs; Sophia Lee; Sandra P. Levison